Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

Enhanced neutralizing antibody and T-cell responses by DNA-based vaccine encoding SARS-CoV-2 spike protein

Researchers from VaxiGen have been investigating the potential for a DNA vaccine boost to VP vaccines against coronavirus disease 2019.

9 Nov 2021

COVID-19 drug candidate with wide-ranging antiviral activity

A new study investigated the antiviral activity and mechanism of action of Brilacidin against multiple human coronaviruses.

9 Nov 2021

Invalidation of potential SARS-CoV-2 protease inhibitors

Researchers identified several structurally disparate compounds that can inhibit the viral protease PLpro and determined whether the identified PLpro inhibitors are truly effective and should be further investigated.

9 Nov 2021

CN Bio and iiCON announce COVID-19 research collaboration

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D programme, to validate the next generation of COVID-19 research tools.

From CN Bio Innovations Ltd 9 Nov 2021

Non-invasive breathing support to treat COVID-19 does not pose higher risk of infection

New research has found that the use of non-invasive breathing support to treat moderate to severe COVID-19 infection, isn’t linked to a heightened infection risk, as currently thought.

9 Nov 2021

Pfizer-BioNTech COVID-19 vaccine is associated with lower viral load in breakthrough infections

Several vaccines have been rapidly developed to help control the COVID-19 pandemic, including the BNT162b2 vaccine (Pfizer/BioNTech). This severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has been shown in both clinical trials and in the real world to be highly efficacious in preventing infection, symptoms, hospitalizations, severe disease, and death related to coronavirus disease (COVID-19).

9 Nov 2021

CDC study shows COVID-19 in newborns is rare

To date, there have been relatively few cases of neonates with COVID-19, and there is limited knowledge of neonatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, recent studies have suggested an increased risk of severe COVID-19 in infants compared to older children, which is based on data that shows an increased rate of hospitalization among infants.

9 Nov 2021

Drinking alcohol and not exercising are modifiable risk factors for SARS-CoV-2

New research from the United Kingdom suggests several factors that increased the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection involved higher alcohol use, Asian/Asian British ethnicity, and obesity. In addition, moderate but not vigorous exercise of more than 10 hours a week was associated with lower susceptibility to infection.

8 Nov 2021

Increase in SARS-CoV-2 seroprevalence in Irish HCWs during third wave of pandemic

Healthcare workers and people they live with are at an increased risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Hospital healthcare workers (HCWs) worldwide have been found to have a higher number of SARS-CoV-2 infections and higher antibody seroprevalence compared to the general population.

8 Nov 2021

Scientists develop a high-throughput, cell-free screening platform for anti-SARS-CoV-2 antibody discovery

Scientists from Northwestern University, USA, have recently developed a high-throughput, automated screening platform to rapidly identify anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. The study is currently available on the bioRxiv* preprint server.

8 Nov 2021

Study reveals cellular mechanism behind older adults' susceptibility to COVID-19

Among the populations most significantly affected by COVID-19 are the elderly and patients with preexisting medical conditions including diabetes, hypertension, obesity, metabolic syndrome, cardiovascular disease and chronic lung diseases like COPD and asthma.

8 Nov 2021

COVID-19 lockdowns and young people's mental health

In the current study, the researchers looked at earlier papers for evidence of the impact of lockdowns on the mental health of the population.

8 Nov 2021

Discovery of potent neutralizing antibodies against SARS-CoV-2 variants

In a recent study, the researchers identify and characterize mAbs that are effective against the wild-type SARS-CoV-2 strain and B.1.351 variant.

8 Nov 2021

Hemin as a potential therapy for COVID-19

The current study explores the antiviral activity of HO-1 induced by hemin against SARS-CoV-2 and attempts to describe the mechanism of its anti-viral action.

8 Nov 2021

SARS-CoV-2 Nsp1 deletions affect protein stability and translation inhibition

A new study discusses the purification of various Nsp1 proteins isolated from several mutated variants of SARS-CoV-2.

8 Nov 2021

Study compares efficacy of BNT162b2 and CoronaVac as the booster dose for COVID-19 vaccination

A recent study reports the immunogenicity and safety of BNT162b2 and CoronaVac as the third dose in CoronaVac-immunized adults.

8 Nov 2021

Household transmission of SARS-CoV-2 delta variant in England

Researchers from Public Health England have been investigating how one of the most dangerous variants, the Delta variant, spreads within households in England.

8 Nov 2021

What are the anti-COVID drugs currently in development?

The first antiviral drugs effective against COVID-19 were recently approved in the UK and USA. A researcher from the Laboratory of Gene Technology has been exploring what we know so far.

8 Nov 2021

Vaccine effectiveness of BNT162b2 third dose against COVID-19

A group of researchers from Maccabi Healthcare Services performed a retrospective cohort study to determine vaccine effectiveness of a third dose.

8 Nov 2021

Ad26.COV2.S vaccine effectiveness for preventing COVID-19

A group of multi-national researchers has expanded on previous research to conduct a preliminary evaluation of the effectiveness of the Ad26.COV2.S vaccine via HER data.

8 Nov 2021